VVP
EDIT icon

Venture Visionary Partners’s Editas Medicine EDIT Stock Holding History

Venture Visionary Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$1.18K – 768
2022
Q2 		$1.18K Buy
+100
New +$1.34K ﹤0.01% 1591

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Venture Visionary Partners's EDIT Position: Q3 2022 in Review

Venture Visionary Partners sold out of Editas Medicine (EDIT) in Q3 2022, closing a stake of 100 shares — an estimated $1.18K sold.

Venture Visionary Partners first reported a position in EDIT in Q2 2022 and held it in 1 quarter. The position peaked at $1.18K in Q2 2022. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

  • Venture Visionary Partners reported no remaining Editas Medicine position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 100 Editas Medicine shares in Q3 2022, an estimated $1.18K.
  • Venture Visionary Partners first reported a position in Editas Medicine in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Editas Medicine position peaked at $1.18K in Q2 2022.
  • 264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.